StreetInsider.com News Articles

Form 8-K Barinthus Biotherapeutic For: Aug 24

Tue, 25 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26970341.html

Form 8-K Barinthus Biotherapeutic For: Aug 24

Tue, 25 Aug 2026 06:05:00 -0400

si-local-file:///var/storage/secattach/20260825/26970341.html

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

GERMANTOWN, Md., Aug. 24, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today provided an update regarding the anticipated closing of its proposed combination with Clywedog Therapeutics, Inc.

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Bio Provides Update on Proposed Combination with Clywedog Therapeutics

Mon, 24 Aug 2026 18:57:00 -0400

Scheme Exchange Ratio determined at 0.111 pursuant to the terms of the merger agreement
Scheme of arrangement expected to become effective on September 3, 2026, with Barinthus Bio ADSs expected to cease trading on Nasdaq prior to market open
Topco common stock expected to commence trading on Nasdaq under the ticker symbol “CLYD” following completion of the proposed combination with Clywedog

Barinthus Biotherapeutics plc (BRNS) Tops Q2 EPS by 2c

Thu, 06 Aug 2026 08:49:49 -0400

Barinthus Biotherapeutics plc (NASDAQ: BRNS) reported Q2 EPS of ($0.26), $0.02 better than the analyst estimate of ($0.28).

For earnings history and earnings-related data on Barinthus Biotherapeutics plc (BRNS) click here.

Form 8-K Barinthus Biotherapeutic For: Aug 06

Thu, 06 Aug 2026 08:49:00 -0400

si-local-file:///var/storage/secattach/20260806/26880087.html

Form 8-K Barinthus Biotherapeutic For: Aug 06

Thu, 06 Aug 2026 08:49:00 -0400

si-local-file:///var/storage/secattach/20260806/26880087.html

Form 10-Q Barinthus Biotherapeutic For: Jun 30

Thu, 06 Aug 2026 08:47:00 -0400

si-local-file:///var/storage/secattach/20260806/26880065.html

Form 10-Q Barinthus Biotherapeutic For: Jun 30

Thu, 06 Aug 2026 08:47:00 -0400

si-local-file:///var/storage/secattach/20260806/26880065.html

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

Thu, 06 Aug 2026 08:00:00 -0400

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing
Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple ascending dose ("MAD") expected in the fourth quarter of 2026

GERMANTOWN, Md., Aug. 06, 2026 (GLOBE NEWSWIRE) -- Barinthus Biotherapeutics plc (NASDAQ: BRNS) (“Barinthus Bio,” or the “Company”), today announced its financial results for the quarter ended June 30, 2026, and provided an overview of the Company’s corporate developments. Barinthus Bio is an immunology and inflammation (“I&I”) company focused on developing therapies

Barinthus Bio Reports Second Quarter 2026 Financial Results and Updates on Corporate Developments

Thu, 06 Aug 2026 08:00:00 -0400

Proposed combination with Clywedog Therapeutics Inc. (“Clywedog”) progressing towards closing
Completed enrollment of 42 planned subjects in the Phase 1 AVALON trial evaluating VTP-1000 in patients with celiac disease; topline data from multiple ascending dose ("MAD") expected in the fourth quarter of 2026